GSK Plc (GSK)
50.86
+0.42
(+0.84%)
USD |
NYSE |
Sep 03, 16:00
50.86
0.00 (0.00%)
After-Hours: 20:00
GSK Research and Development Expense (TTM) : 9.289B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 9.289B |
| March 31, 2026 | 9.040B |
| December 31, 2025 | 8.788B |
| September 30, 2025 | 8.298B |
| June 30, 2025 | 8.047B |
| March 31, 2025 | 7.787B |
| December 31, 2024 | 7.769B |
| September 30, 2024 | 7.011B |
| June 30, 2024 | 6.945B |
| March 31, 2024 | 6.790B |
| December 31, 2023 | 6.555B |
| September 30, 2023 | 7.045B |
| June 30, 2023 | 6.764B |
| March 31, 2023 | 6.667B |
| December 31, 2022 | 6.650B |
| September 30, 2022 | 6.415B |
| June 30, 2022 | 6.824B |
| March 31, 2022 | 6.866B |
| December 31, 2021 | 6.915B |
| September 30, 2021 | 6.860B |
| June 30, 2021 | 6.380B |
| March 31, 2021 | 6.406B |
| December 31, 2020 | 6.277B |
| September 30, 2020 | 6.025B |
| June 30, 2020 | 6.042B |
| Date | Value |
|---|---|
| March 31, 2020 | 5.799B |
| December 31, 2019 | 5.680B |
| September 30, 2019 | 5.520B |
| June 30, 2019 | 5.336B |
| March 31, 2019 | 5.220B |
| December 31, 2018 | 5.187B |
| September 30, 2018 | 5.407B |
| June 30, 2018 | 5.489B |
| March 31, 2018 | 5.845B |
| December 31, 2017 | 5.776B |
| September 30, 2017 | 5.399B |
| June 30, 2017 | 5.225B |
| March 31, 2017 | 4.747B |
| December 31, 2016 | 4.655B |
| September 30, 2016 | 4.727B |
| June 30, 2016 | 4.668B |
| March 31, 2016 | 4.676B |
| December 31, 2015 | 4.790B |
| September 30, 2015 | 4.815B |
| June 30, 2015 | 4.936B |
| March 31, 2015 | 5.117B |
| December 31, 2014 | 5.247B |
| September 30, 2014 | 3.924B |
| June 30, 2014 | 3.931B |
| March 31, 2014 | 3.943B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| AstraZeneca PLC | 14.21B |
| Eli Lilly & Co. | 14.60B |
| Merck & Co., Inc. | 27.26B |
| Pfizer Inc. | 10.82B |
| Sanofi | 9.453B |